Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Teicoplanin is a glycopeptide antibiotic. It is a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, termed teicoplanin A3-1, a fused ring structure to which two carbohydrates (mannose and N-acetylglucosamine) are attached. The major and minor components also contain a third carbohydrate moiety, β-D-glucosamine, and differ only by the length and conformation of a side chain attached to it. [Wikipedia] (en)
|
http://linked.open...generalReferences
| - # de Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, Tramarin A: Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother. 1992 Oct;36(10):2192-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1444298 # Bernareggi A, Borghi A, Borgonovi M, Cavenaghi L, Ferrari P, Vekey K, Zanol M, Zerilli LF: Teicoplanin metabolism in humans. Antimicrob Agents Chemother. 1992 Aug;36(8):1744-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1416858 # Yano R, Nakamura T, Tsukamoto H, Igarashi T, Goto N, Wakiya Y, Masada M: Variability in teicoplanin protein binding and its prediction using serum albumin concentrations. Ther Drug Monit. 2007 Aug;29(4):399-403. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17667792 # Pryka RD, Rodvold KA, Rotschafer JC: Teicoplanin: an investigational glycopeptide antibiotic. Clin Pharm. 1988 Sep;7(9):647-58. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2977108 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| |
http://linked.open...ugbank/indication
| - For the treatment of bacterial infections caused by susceptible microorganisms. (en)
|
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Teicoplanin inhibits peptidoglycan polymerization, resulting in inhibition of bacterial cell wall synthesis and cell death. (en)
|
http://linked.open.../drugbank/synonym
| - Teichomycin (en)
- TEIC (en)
- Teichomycin a2 factor 2 (en)
|
http://linked.open...nk/proteinBinding
| |
http://linked.open...ynthesisReference
| - Emil Toma, Madeleine Ravaoarinoro, "Production and characteristics of anti-teicoplanin polyclonal antibody." U.S. Patent US5612459, issued November, 1990. (en)
|
http://linked.open...y/mesh/hasConcept
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...ugbank/absorption
| - Teicoplanin is poorly absorbed after oral administration but is 90% bioavailable when administered intramuscularly. (en)
|
http://linked.open.../affectedOrganism
| - Gram-positive Bacteria (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |